T0	Participants 396 505	postmenopausal women who had received alendronate daily or weekly in tablets with or without enteric coating.
T1	Participants 581 705	75 volunteers, aged 45-58 with moderate to severe osteopenia (T-score lower than -2 SD) assessed by quantitative ultrasound.